KRTX - Karuna Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
65.25
-8.26 (-11.24%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close73.51
Open74.52
Bid65.40 x 3100
Ask66.60 x 800
Day's Range63.53 - 74.52
52 Week Range11.24 - 152.00
Volume640,590
Avg. Volume590,058
Market Cap1.5B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • Business Wire

    Karuna Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference

    Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that Andrew Miller, Ph.D., founder and chief operating officer at Karuna, will present and host investor meetings at the Piper Jaffray 31st Annual Healthcare Conference being held at the Lotte New York Palace in New York, NY. Karuna is a clinical-stage biopharmaceutical company committed to developing and delivering first-in-class therapies with the potential to transform the lives of people with CNS disorders – which remain among the most disabling and potentially fatal disorders worldwide.

  • Business Wire

    Karuna Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock

    Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced the pricing of its previously announced underwritten public offering of 2,600,000 shares of its common stock at a price to the public of $96.00 per share. The gross proceeds to Karuna from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $250.0 million. The offering is expected to close on November 25, 2019, subject to customary closing conditions.

  • Business Wire

    Karuna Therapeutics Announces Proposed Public Offering of Common Stock

    Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that it has commenced an underwritten public offering of 2,600,000 shares of its common stock. Karuna intends to grant the underwriters a 30-day option to purchase an additional 390,000 shares of its common stock, at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering may be completed, or as to the actual size and terms of the offering.

  • Business Wire

    Karuna Therapeutics Announces KarXT Met Primary Endpoint in Phase 2 Clinical Trial of Acute Psychosis in Patients with Schizophrenia

    Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced results from its Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia. In the clinical trial, KarXT demonstrated a statistically significant and clinically meaningful 11.6 point mean reduction in total Positive and Negative Syndrome Scale (PANSS) score compared to placebo (p

  • Business Wire

    Karuna Therapeutics Schedules Webcast and Conference Call to Announce Results from its Phase 2 Clinical Trial of KarXT for the Treatment of Psychosis in Patients with Schizophrenia

    Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced it will hold a webcast and conference call on Monday, November 18, 2019 at 8:30 a.m. EST to provide results from its Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia. The dial-in numbers are 1-855-548-1216 for domestic callers and 1-409-216-6318 for international callers. A live webcast of the conference call will also be available on the investor relations page of the Karuna Therapeutics corporate website at www.karunatx.com.

  • Business Wire

    Karuna Therapeutics Reports Third Quarter 2019 Financial Results and Provides General Business Update

    BOSTON-- -- Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia remains on track with topline data expected in late 2019 Phase 1b clinical trials for the treatment of psychosis in Alzheimer’s disease and pain on track to commence by the end of 2019 Cash, cash equivalents and short-term investment balance of $161.6 million to fund development of novel ...

  • Business Wire

    Karuna Therapeutics Announces Pricing of Upsized Initial Public Offering

    Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions, today announced the pricing of its upsized initial public offering of 5,578,124 shares of common stock at a public offering price of $16.00 per share. In addition, Karuna has granted the underwriters a 30-day option to purchase up to 836,718 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions.